133 related articles for article (PubMed ID: 22416898)
1. Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS.
Warsame R; Kohut IE; Dispenzieri A
Eur J Haematol; 2012 Jun; 88(6):549-50. PubMed ID: 22416898
[TBL] [Abstract][Full Text] [Related]
2. Successful bortezomib-based treatment in POEMS syndrome.
Tang X; Shi X; Sun A; Qiu H; Gu B; Zhou H; Xue S; Liu Y; Ruan C; Wu D
Eur J Haematol; 2009 Dec; 83(6):609-10. PubMed ID: 19674063
[No Abstract] [Full Text] [Related]
3. Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature.
Zeng K; Yang JR; Li J; Wei Q; Yang YM; Liu T; Niu T
Acta Haematol; 2013; 129(2):101-5. PubMed ID: 23171959
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation.
Vannata B; Laurenti L; Chiusolo P; Sorà F; Balducci M; Sabatelli M; Luigetti M; Giannotta C; De Stefano V; Leone G; Sica S
Am J Hematol; 2012 Jun; 87(6):641-2. PubMed ID: 22488443
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib: a new therapeutic option for POEMS syndrome.
Kaygusuz I; Tezcan H; Cetiner M; Kocakaya O; Uzay A; Bayik M
Eur J Haematol; 2010 Feb; 84(2):175-7. PubMed ID: 19732138
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with bortezomib and thalidomide for POEMS syndrome.
Ohguchi H; Ohba R; Onishi Y; Fukuhara N; Okitsu Y; Yamamoto J; Ishizawa K; Ichinohasama R; Harigae H
Ann Hematol; 2011 Sep; 90(9):1113-4. PubMed ID: 21153416
[No Abstract] [Full Text] [Related]
8. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Kropff M; Bisping G; Schuck E; Liebisch P; Lang N; Hentrich M; Dechow T; Kröger N; Salwender H; Metzner B; Sezer O; Engelhardt M; Wolf HH; Einsele H; Volpert S; Heinecke A; Berdel WE; Kienast J;
Br J Haematol; 2007 Aug; 138(3):330-7. PubMed ID: 17614819
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
[TBL] [Abstract][Full Text] [Related]
10. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
11. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
[TBL] [Abstract][Full Text] [Related]
12. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
[TBL] [Abstract][Full Text] [Related]
13. [IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
Adam Z; Feit J; Krejcí M; Pour L; Vasků V; Cermáková Z; Mayer J; Hájek R
Vnitr Lek; 2009 Oct; 55(10):981-90. PubMed ID: 19947244
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
Corso A; Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Algarotti A; Pascutto C; Lazzarino M
Eur J Haematol; 2009 Nov; 83(5):449-54. PubMed ID: 19519727
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
Leblebjian H; Noonan K; Paba-Prada C; Treon SP; Castillo JJ; Ghobrial IM
Am J Hematol; 2015 Jun; 90(6):E122-3. PubMed ID: 25703132
[No Abstract] [Full Text] [Related]
18. [Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
Yuan ZG; Hou J; Zhou F; Fu WJ; Chen YB; Xi H; Yang SL
Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):653-5. PubMed ID: 17343194
[TBL] [Abstract][Full Text] [Related]
19. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
Bao L; Lu XJ; Zhang XH; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
[TBL] [Abstract][Full Text] [Related]
20. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]